Montbonnot (France), November 18, 2019

Shanghai UJI Network Technology Co., Ltd, Technidata’s distributor of TD Biobank in China, Hong Kong and Macau has announced that TD Biobank is running live in an operational environment at Jiangsu Purecell Biomedical Co., Ltd. Implementation began in April 2019 and went live one month later.

Jiangsu Purecell is an NGO-funded medical preparation manufacturing company that currently houses 50,000 samples and collects more than 500 samples per day. Specimens mainly include stem cells such as umbilical cord mesenchymal stem cells, adipose-derived stem cells, placental stem cells, amniotic membrane stem cells, deciduous teeth stem cells, etc. Purecell is also actively involved in developing immune cell technologies.

"TD Biobank has improved Purecell’s daily workflow and approval system. It has helped with interdepartmental communication and coordination between production, quality, inspection and transportation departments. Sample management and access have been vastly improved. Purecell is now able to integrate data that can be directly viewed at their group headquarters," says Daniel Li, Product Manager at UJI.

Since Purecell currently operates over a large geographical area in China, this is a significant boost to their activity.

About PureCell

Jiangsu Purecell Biomedical Co., Ltd. is located in the Tengfei Innovation Park of Suzhou Industrial Park in Jiangsu Province. The company is devoted to the research and development of stem and immune cell technology and their clinical applications, the creation of industrial chains for advanced cell research, clinical research and marketing.

Jiangsu Purecell Biomedical is committed to the standardized preparation of various stem cells, conducts clinical research of stem cells, and develops new stem cell drugs. At present, the company actively promotes clinical research on "umbilical cord mesenchymal stem cells for decompensated hepatitis B cirrhosis" and "umbilical cord mesenchymal stem cells combined with biomaterials for the treatment of degenerative knee arthritis".

Corresponding animal experiments and clinical research are rapidly advancing. In the field of immunocyte tumor therapy, they have deployed new technologies. NK, mTCM, ACTL and other immunocyte technologies are mature and perfect. CART technology has been clinically verified, and its efficacy is comparable to that of their foreign counterparts. Universal CART technology is being developed. They are also actively involved in developing products and technologies applied to anti-aging technology, functional medical testing services and stem cell active factor RE series and so on.

They have SGS ISO9001, ISO13485, GMP ISO14001 and CE certification.

Learn more about TD Biobank: www.biobank-solutions.com

About TECHNIDATA - www.technidata-web.com

With over 40 years’ experience in the field of laboratory management, TECHNIDATA is a leading global software supplier for clinical, anatomic-pathology laboratories and biobank information systems. Developed in full compliance with the ISO 9001/ISO 13485 quality standards, TECHNIDATA software products are distributed in more than 25 countries worldwide and cover all the clinical laboratory disciplines: biochemistry, hematology, immunology, virology, microbiology, blood banking, histology/cytology, genetics, and biobanking.

Press Contact: Carine HUGUEL – Marketing & Communication Manager, carine.huguel@technidata-web.com

Products and services:
- Laboratory Information Systems (Livextens suite)
- Middleware solutions (TD Harmony suite)
- Instrument workstations
- Point-of-Care Testing Management
- Web-based requests and results module
- Services: Consulting, Development, Support, Training activities